ArticleNature cancer2023
Structural surfaceomics reveals an AML-specific conformation of integrin β
Abstract read
In one paragraph
Article in Nature cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Murine IL-2 outperforms human IL-2 in supporting the survival of naïve mouse CD8 T cells in vitro.Life science alliance · 2026Article
- Preclinical advances and mechanistic insights of CAR-T therapy for acute myeloid leukemia: from target iteration to microenvironment regulation.Annals of medicine · 2026Review
- Pediatric AML CAR T cell therapy.Molecular therapy. Oncology · 2026Review
- The search for safe and effective CAR-T targets in AML.Blood cancer journal · 2026Review
- Extending structural surfaceomics to identify aberrant conformations of tumor surface proteins as potential immunotherapy targets.bioRxiv : the preprint server for biology · 2026Article
- Mining antibody functionality via AI-guided structural landscape profiling.Nature communications · 2026Article
- Targeting splicing-derived neoantigens for precision cancer immunotherapy.Frontiers in immunology · 2026Review
- Targeting the tumor cell-intrinsic ITGB2 axis inhibits melanoma progression.Molecular cancer · 2025Article
- Structural and Functional Analysis of GGPPS Inhibition as a Therapeutic Mechanism for Acute Myeloid Leukemia (AML).Research square · 2025Article
- Effective imaging and treatment of Acute Myeloid Leukemia with radiotheranostics targeting the activated conformation of integrin-βeta2.Research square · 2025Article
- Strategic innovations: Tackling challenges of immunotherapy in acute myeloid leukemia.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- IGSF9-targeted therapy inhibits the progression of acute myeloid leukemia.Blood advances · 2025Article
- CAR-T cell therapy for cancer: current challenges and future directions.Signal transduction and targeted therapy · 2025Review
- Emerging Strategies of Cell and Gene Therapy Targeting Tumor Immune Microenvironment.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Review
- Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia.Nature communications · 2025Article
- Engineered Proteins and Chemical Tools to Probe the Cell Surface Proteome.Chemical reviews · 2025Review
- Conformation-sensitive targeting of CD18 depletes M2-like tumor-associated macrophages resulting in inhibition of solid tumor progression.Journal for immunotherapy of cancer · 2025Article
- CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant.Nature cancer · 2025Article
- CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells.Blood cancer discovery · 2025Article
- Challenges in the preclinical design and assessment of CAR-T cells.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Kamal MandalDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Gianina WicaksonoDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Clinton YuDepartment of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA.
Jarrett J AdamsThe Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Michael R HoopmannInstitute for Systems Biology, Seattle, WA, USA.
William C TempleDepartment of Pediatrics, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Adila IzgutdinaDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-3296-3261
Bonell Patiño EscobarDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-2622-4822
Maryna GorelikThe Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Christian H IhlingDepartment of Pharmaceutical Chemistry and Bioanalytics, Institute of Pharmacy, Martin-Luther University Halle-Wittenberg, Halle, Germany.ORCID 0000-0003-2419-4391
Matthew A NixDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-7741-5368
Akul NaikDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
William H XieUCSF/Gladstone Institute for Genomic Immunology, San Francisco, CA, USA.
Juwita HübnerDepartment of Pediatrics, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Lisa A RollinsCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital-Texas Children's Hospital, Houston, TX, USA.
Sandy M ReidCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital-Texas Children's Hospital, Houston, TX, USA.
Emilio RamosDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Corynn KasapDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Veronica SteriHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Juan Antonio Camara SerranoHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Fernando SalangsangHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Paul PhojanakongHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Melanie McMillanDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Victor GavallosDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Andrew D LeavittDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Aaron C LoganDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Cliona M RooneyCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital-Texas Children's Hospital, Houston, TX, USA.
Justin EyquemUCSF/Gladstone Institute for Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0001-8262-1190
Andrea SinzDepartment of Pharmaceutical Chemistry and Bioanalytics, Institute of Pharmacy, Martin-Luther University Halle-Wittenberg, Halle, Germany.ORCID 0000-0003-1521-4899
Benjamin J HuangDepartment of Pediatrics, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-6996-0833
Elliot StieglitzDepartment of Pediatrics, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-7032-4623
Catherine C SmithDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Robert L MoritzInstitute for Systems Biology, Seattle, WA, USA.ORCID 0000-0002-3216-9447
Sachdev S SidhuThe Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0001-7755-5918
Lan HuangDepartment of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA.ORCID 0000-0002-3140-4687
Arun P WiitaDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA. arun.wiita@ucsf.edu.ORCID 0000-0002-7465-6964
Funding
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kate Taylor Shumate · 1999 to 2026
$209.7MProteomics of the Proteasome Interacting NetworksR01GM074830 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI HUANG, LAN · 2005 to 2022
$6.1MResearch Training in Childhood CancerT32CA128583 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Eric Alejandro Sweet-Cordero · 2007 to 2026
$6.0MShortening the development cycle time of Trans Proteomic Pipeline tools with high performance computingR01GM087221 · NIGMS · INSTITUTE FOR SYSTEMS BIOLOGY · PI DEUTSCH, ERIC, MORITZ, ROBERT L · 2010 to 2021
$6.0MSupplement: Advancing Proteomics Technologies to Decipher the Ubiquitin-Proteasome SystemR35GM145249 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI Lan Huang · 2022 to 2026
$3.2MA multi-faceted intervention to promote breast cancer hormone receptor testing in TanzaniaK08CA263299 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Dianna L. Ng · 2021 to 2026
$1.3MCo-targeting BET Bromodomain Proteins and Aberrant Signaling in AML.K08CA256489 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUANG, BENJAMIN · 2021 to 2025
$1.2MStructural dynamics and function of the COP9 signalosomeR01GM130144 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI HUANG, LAN · 2018 to 2021
$1.2MAcquisition of Fusion Lumos Orbitrap mass spectrometerS10OD026936 · OD · INSTITUTE FOR SYSTEMS BIOLOGY · PI MORITZ, ROBERT L · 2019 to 2019
$600kStructural Surfaceomics: A Strategy for Immunotherapy Target DiscoveryR21CA263229 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIITA, ARUN P. · 2021 to 2022
$424kNCI NIH HHS K08 CA256489NCI NIH HHS K08 CA263299NCI NIH HHS P30 CA082103NCI NIH HHS R21 CA263229NCI NIH HHS T32 CA128583NIGMS NIH HHS R01 GM074830NIGMS NIH HHS R01 GM087221NIGMS NIH HHS R01 GM130144NIGMS NIH HHS R35 GM145249NIH HHS S10 OD026936
Abstract
Safely expanding indications for cellular therapies has been challenging given a lack of highly cancer-specific surface markers. Here we explore the hypothesis that tumor cells express cancer-specific surface protein conformations that are invisible to standard target discovery pipelines evaluating gene or protein expression, and these conformations can be identified and immunotherapeutically targeted. We term this strategy integrating cross-linking mass spectrometry with glycoprotein surface capture 'structural surfaceomics'. As a proof of principle, we apply this technology to acute myeloid leukemia (AML), a hematologic malignancy with dismal outcomes and no known optimal immunotherapy target. We identify the activated conformation of integrin β
Indexed as
Leukemia, Myeloid, AcuteReceptors, Chimeric AntigenHumansImmunotherapy, AdoptiveIntegrinsT-LymphocytesIntegrinsReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.